CompaniesOraya Therapeutics

Oraya Therapeutics

defunct
About

Defunct Company

Areas of Focus

Categories

Terminally AcquiredBankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (6)
View all

Total Trials

6

As Lead Sponsor

6

As Collaborator

0

Total Enrollment

816

By Phase

PHASE2: 2NA: 3PHASE1: 1

By Status

UNKNOWN: 4WITHDRAWN: 1COMPLETED: 1
Clinical Trials Pipeline6 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
Today
NCT01217762
NCT01016873
NCT01339949
NCT01516294
NCT01521819
NCT01521065
Hover over trial bars to see details

Recent Trials

NCT01521065Lead Sponsor
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
PHASE2Unknown
500 participants
Started: Sep 30, 2012 · Completed: Oct 31, 2016
NCT01521819Lead Sponsor
Iray for Vascularized Pigment Epithelial Detachment (VPED) Secondary to Age Related Macular Degeneration
NAUnknown
12 participants
Started: Aug 31, 2012 · Completed: Aug 31, 2014
NCT01516294Lead Sponsor
IRay to Treat Polypoidal Choroidal Vasculopathy (PCV) Secondary to Age-Related Macular Degeneration (AMD
NAUnknown
12 participants
Started: Jan 31, 2012 · Completed: Mar 31, 2014
NCT01339949Lead Sponsor
Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)
NAWithdrawn
Started: Jun 30, 2011 · Completed: Oct 31, 2014
NCT01016873Lead Sponsor
INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD
PHASE2Completed
230 participants
Started: Nov 30, 2009 · Completed: Apr 30, 2014
View all 6 trials →
Funding History (5)
D
May 13, 2014
Filing
D/A
Apr 5, 2011
Filing
D
Dec 29, 2010
Filing
D
Jul 22, 2009
Filing
D
Apr 23, 2009
Filing
Oraya Therapeutics | Biotech Hunter | Biotech Hunter